Results 251 to 260 of about 154,948 (311)

The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska, Ryan Chung, Salman Ramjaun, Danyao Jin, Ciara Doherty, Kieran McCafferty, Samuel Seidu   +6 more
wiley   +1 more source

Type 2 Diabetes Mellitus Modifies the Prognostic Value of LDL Particle Size in Statin-treated Patients With Coronary Artery Disease: A Large-scale Cohort Study. [PDF]

MedComm (2020)
Bian X, He J, Song C, Zhang R, Yuan S, Gao G, Dou K.   +6 more
europepmc   +1 more source

Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis).
Frances Perry, Silvia J. Leon, Kate Polecina, Ruth Getachew, Nicole Askin, Thomas Ferguson, Reid Whitlock, Zihe Zheng, Carolina Aldworth, Arvind Katta, Jacob Earl, Mauricio Beller Ferri, Navdeep Tangri   +12 more
wiley   +1 more source

Gender, age, and socioeconomic position-specific associations between illness perception and diabetes-related distress: cross-sectional analysis among people with type 2 diabetes. [PDF]

Front Endocrinol (Lausanne)
Landstra EN, de Klerk F, van Schalkwijk D, Jansen H, Valke LLFG, Smeets T, Mark RE, Soedamah-Muthu SS.   +7 more
europepmc   +1 more source

Liver Fibrosis and IRS1 rs2972146 Are Associated With Weight Loss Response After Metabolic Bariatric Surgery

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aims Weight loss after metabolic bariatric surgery (MBS) is heterogeneous, and the contribution of liver histology and genetic susceptibility to insufficient weight loss (IWL) or weight regain (WR) remains unclear. We assessed the prevalence of IWL and WR after MBS and their association with liver histology and metabolic ...
Felice Cinque, Marica Meroni, Sara Badiali, Miriam Longo, Erika Paolini, Elisa Galfrascoli, Giovanna Oberti, Giuseppina Pisano, Gabriele Maffi, Matteo Mureddu, Elena Corbetta, Valentina Scimè, Emma Calzavara, Francesca Alletto, Annalisa Cespiati, Luigi Boni, Anna Ludovica Fracanzani, Paola Dongiovanni, Rosa Lombardi   +18 more
wiley   +1 more source

Metformin Use Is Associated With Better Cognitive Performance in Older Adults With Type 2 Diabetes: Exploratory Analysis of Vitamin B12 and Methylmalonic Acid Pathways in NHANES 2011–2014

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Metformin, the first‐line treatment for Type 2 diabetes mellitus (T2DM), may be neuroprotective but also lowers serum vitamin B12 by ~19%, raising concern that B12 depletion could offset this benefit. We used modern exploratory causal mediation methods in a nationally representative sample to test whether vitamin B12 and methylmalonic ...
Danial Fotros, Hanieh Sakhdari, Andrew C. Shin   +2 more
wiley   +1 more source

Multiscale Brain Structural Network Reorganization in Diabetic Retinopathy Using Regional Radiomics Similarity Networks. [PDF]

Diabetes Metab Syndr Obes
Hu D, Hu RY, Cheng YY, Yu FL, Huang X.
europepmc   +1 more source

Effects of GLP‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review

The FEBS Journal, EarlyView.
This systematic review evaluated 17 studies (12 preclinical and five clinical) on GLP‐1 receptor agonists in type 2 diabetes, demonstrating effects on the gut microbiota and metabolic improvement. The studies showed an increase in Bacteroidetes, Lactobacillus, and Akkermansia, and a reduction in Firmicutes.
Ranicleide Santos Dantas, Lucas Vinícius Souza Santos, André Gustavo Carvalho de Oliveira, Marina dos Santos Barreto, Deise Maria Rego Rodrigues Silva, Pedro Henrique Macedo Moura, Eloia Emanuelly Dias Silva, Ronaldy Santana Santos, Lucas Alves da Mota Santana, Rajiv Gandhi Gopalsamy, Adriana Gibara Guimarães, Lysandro Pinto Borges   +11 more
wiley   +1 more source

Individual and Contextual Socioeconomic Position on Type 2 Diabetes Risk in LMICs: A Multilevel Analysis. [PDF]

Ann N Y Acad Sci
Fahimi R, Alrubayyi A, Hassan M, Barber TM, Uthman OA.   +4 more
europepmc   +1 more source

White and gray matter diffusion-derived differences in type 2 diabetes mellitus: a free-water-corrected diffusion MRI study. [PDF]

Front Med (Lausanne)
Lin D, Zheng J, Zeng T, Huang Z, Xiong H, Cai T, Wang X.   +6 more
europepmc   +1 more source